Media headlines about Endo International (NASDAQ:ENDP) (TSE:ENL) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endo International earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.4639985614005 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern’s analysis:
Shares of Endo International (ENDP) traded down $0.24 during trading on Monday, hitting $6.30. 5,140,000 shares of the company traded hands, compared to its average volume of 5,720,000. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 10.78. Endo International has a 12-month low of $5.77 and a 12-month high of $14.45. The stock has a market capitalization of $1,460.00, a PE ratio of -0.33, a PEG ratio of 2.28 and a beta of 0.29.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million for the quarter, compared to analyst estimates of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The firm’s revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the business earned $1.01 earnings per share. analysts predict that Endo International will post 3.68 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on the stock. ValuEngine cut shares of Endo International from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Leerink Swann assumed coverage on shares of Endo International in a research report on Tuesday, January 2nd. They set an “outperform” rating and a $12.00 target price for the company. Zacks Investment Research cut shares of Endo International from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Vetr cut shares of Endo International from a “strong-buy” rating to a “buy” rating and set a $8.92 target price for the company. in a research report on Monday, December 18th. Finally, Citigroup decreased their price target on shares of Endo International from $9.00 to $7.00 and set a “neutral” rating for the company in a report on Friday, November 10th. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.79.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Endo International (ENDP) Share Price” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/05/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-endo-international-endp-share-price.html.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.